A detailed history of Cerity Partners LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cerity Partners LLC holds 199,817 shares of VRTX stock, worth $100 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares
199,817
Previous 194,732 2.61%
Holding current value
$100 Million
Previous $81.4 Million 15.06%
% of portfolio
0.25%
Previous 0.22%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $2 Million - $2.47 Million
5,085 Added 2.61%
199,817 $93.7 Million
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $26 Million - $28.5 Million
63,837 Added 48.77%
194,732 $81.4 Million
Q4 2023

Jan 26, 2024

BUY
$343.0 - $410.68 $20.2 Million - $24.2 Million
58,974 Added 82.0%
130,895 $53.3 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $7.86 Million - $8.42 Million
23,232 Added 47.72%
71,921 $25 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $2.82 Million - $3.15 Million
8,958 Added 22.55%
48,689 $17.1 Million
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $10.1 Million - $11.5 Million
35,687 Added 882.47%
39,731 $12.5 Million
Q4 2022

Feb 15, 2023

BUY
$285.76 - $321.48 $362,057 - $407,315
1,267 Added 45.62%
4,044 $1.17 Million
Q3 2022

Nov 10, 2022

BUY
$273.83 - $305.53 $61,064 - $68,133
223 Added 8.73%
2,777 $804,000
Q2 2022

Aug 10, 2022

BUY
$234.96 - $292.55 $170,111 - $211,806
724 Added 39.56%
2,554 $720,000
Q1 2022

Apr 25, 2022

SELL
$221.42 - $260.97 $111,595 - $131,528
-504 Reduced 21.59%
1,830 $478,000
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $145,325 - $183,452
821 Added 54.26%
2,334 $515,000
Q3 2021

Oct 25, 2021

BUY
$181.39 - $202.99 $7,799 - $8,728
43 Added 2.93%
1,513 $274,000
Q2 2021

Aug 11, 2021

BUY
$187.49 - $221.1 $20,061 - $23,657
107 Added 7.85%
1,470 $296,000
Q1 2021

Aug 11, 2021

SELL
$207.02 - $241.31 $6,210 - $7,239
-30 Reduced 2.15%
1,363 $293,000
Q1 2021

May 12, 2021

BUY
$207.02 - $241.31 $23,186 - $27,026
112 Added 8.74%
1,393 $299,000
Q4 2020

Feb 11, 2021

BUY
$207.01 - $276.09 $39,952 - $53,285
193 Added 17.74%
1,281 $303,000
Q3 2020

Nov 12, 2020

SELL
$255.65 - $303.1 $22,497 - $26,672
-88 Reduced 7.48%
1,088 $296,000
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $3,156 - $4,141
14 Added 1.2%
1,176 $341,000
Q1 2020

May 14, 2020

BUY
$199.77 - $247.81 $19,977 - $24,781
100 Added 9.42%
1,162 $276,000
Q4 2019

Feb 14, 2020

SELL
$166.71 - $223.91 $108,528 - $145,765
-651 Reduced 38.0%
1,062 $233,000
Q3 2019

Oct 30, 2019

BUY
$166.23 - $187.09 $17,454 - $19,644
105 Added 6.53%
1,713 $290,000
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $53,662 - $62,060
-326 Reduced 16.86%
1,608 $295,000
Q1 2019

May 14, 2019

SELL
$163.73 - $194.7 $71,713 - $85,278
-438 Reduced 18.47%
1,934 $356,000
Q4 2018

Feb 06, 2019

SELL
$151.91 - $192.21 $20,963 - $26,524
-138 Reduced 5.5%
2,372 $393,000
Q3 2018

Nov 15, 2018

BUY
$167.73 - $192.74 $172,426 - $198,136
1,028 Added 69.37%
2,510 $484,000
Q2 2018

Aug 15, 2018

BUY
$145.72 - $169.96 $215,957 - $251,880
1,482 New
1,482 $252,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Cerity Partners LLC Portfolio

Follow Cerity Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cerity Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cerity Partners LLC with notifications on news.